CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Slides:

Advertisements

Similar presentations

McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the CHARM investigators Relationship of dose of background angiotensin-converting.

Advertisements

Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.

Losartan Heart Failure Survival Study ELITE II Losartan Heart Failure Survival Study ELITE II A Multicenter, Double-Blind, Randomized, Parallel, Captopril-Controlled.

Purpose To determine whether metoprolol controlled/extended release

Carvedilol Or Metoprolol European Trial Presented at European Heart Failure Meeting 2003 COMET Trial.

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.

MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.

חזק בהגנה לבבית Valsartan in Heart Failure

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.

SOLVD (Studies of Left Ventricular Dysfunction)

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.

Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Massie I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Barry Massie and Peter Carson Executive Committee M. Komajda, R. McKelvie,

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Randomized, double-blind, multicenter, controlled trial.

0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.

Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr ;348(15) : PREVENT (Warfarin) Trial.

Update on Valsartan Špinar J.. System renin-angiotensin-aldosteron angiotensinogen angiotensin I angiotensin II aldosteron ANP,BNP thirst resorp. Na +

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

CAST: Cardiac Arrhythmia Suppression Trial Purpose To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic.

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

CIBIS II Cardiac Insufficiency Bisoprolol Study

The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.

Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support SURVIVE-WSURVIVE-W Presented at The American Heart Association Scientific.

Impact of ISDN-hydralazine on mortality and morbidity of African-American patients with Heart Failure A-Heft Trial Presented at American Heart Association.

UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP

ISIS-4: Fourth International Study of Infarct Survival Purpose To assess the separate and combined effects on all-cause mortality of adding early captopril,

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

4S: Scandinavian Simvastatin Survival Study

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

NSTE Acute Coronary Syndromes

OVERTURE FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Milton Packer, M.D., FACC Columbia University College of Physicians.

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure Results of a Veterans Administration Cooperative Study (V-HEFT I) Multicenter,

Eric J Robinson, M.D. Cardiologist April 25, 2015

Clinical Trial Commentary

NYHA III* or IV heart failure ACE-I + loop diuretic ± digoxn

HOPE: Heart Outcomes Prevention Evaluation study

The IDEAL Study Reference

Scandinavian Simvastatin Survival Study (4S)

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

Section III: Neurohormonal strategies in heart failure

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

The Hypertension in the Very Elderly Trial (HYVET)

Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

Updates in Heart Failure:

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

Presentation transcript:

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients with severe congestive heart failure Reference The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429–35.

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study - TRIAL DESIGN - Design Multicenter, multinational, randomized, double-blind, placebo- controlled Patients 253 patients with severe congestive heart failure (NYHA class IV) and heart size >600 (men) or >500 mL/m 2 (women), and receiving a diuretic and digoxin; patients with MI in previous 2 months excluded Follow up and primary endpoint Primary endpoint: all-cause mortality. Mean 188 days follow up Treatment Placebo or enalapril initiated at 5 mg twice daily; increased to 10 mg twice daily after 1 week if no side effects, then to maximum 20 mg twice daily according to clinical response

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study - RESULTS - Trial halted early on recommendation of Ethical Review Committee because of evident benefit of enalapril Significant reduction in all-cause mortality in enalapril group at 6 months and 1 year, with overall relative risk reduction of 27% (39 vs. 54%, P=0.003) Reduction in mortality entirely attributed to reduction in death due to progression of heart failure No difference in incidence of sudden cardiac death within the two groups NYHA class improved in significantly higher proportion of enalapril group (42 vs. 22%, P<0.001) Withdrawal due to hypotension higher in enalapril group, but overall withdrawal rate similar in the two groups

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study - RESULTS continued - Months after randomization Probability Placebo: Enalapril: Cumulative probability of death Placebo Enalapril CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429–35.

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study - RESULTS continued - P Mortality at 6 months (180 days) Mortality at 1 year (360 days) Total mortality All-cause mortality Placebo (n=126) No. (%) Enalapril (n=127) No. (%) CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429–35. (44) (52) (54) (26) (36) (39) Reduction in relative risk (%)

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study - RESULTS continued - P Cardiac death within 24 h of new symptoms Sudden cardiac death (within 1 h of new symptoms) Progression of congestive heart failure Other cardiac death Cardiac causes of death Placebo (n=126) Enalapril (n=127) CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429– > No. of deaths

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study - SUMMARY - In patients with severe congestive heart failure and increased heart size, enalapril: Reduced all-cause mortality Reduced death due to progression of heart failure Did not change incidence of sudden cardiac death